News & Events
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy (opens in a new tab)
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx ® platform provides high-resolution functional biological understanding of live biotherapeutics and supports the advancement of Seres’ portfolio, including Phase 2-ready…
Publication of interim report Q3 2025 (opens in a new tab)
OSLO, NORWAY – November 27, 2025: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the interim report for Q3, and the first nine months of 2025. The report is available as an attached file to this release and on the Company’s website. Below is a summary of the report. Ronny Hermansen, CEO of Genetic Analysi…
Genetic Analysis AS announces milestone in the IBD diagnostic test development project – completion of biomarker panel for GA-map® IBD Precision Dx (opens in a new tab)
The post Genetic Analysis AS announces milestone in the IBD diagnostic test development project – completion of biomarker panel for GA-map® IBD Precision Dx appeared first on Genetic Analysis.…
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates (opens in a new tab)
Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other…
Clarivate – Women’s Health Companies to Watch (opens in a new tab)
View article…
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 (opens in a new tab)
CAMBRIDGE, Mass. , Oct. 30, 2025 (GLOBE NEWSWIRE) — Seres Therapeutics , Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financial…
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 (opens in a new tab)
Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant (AMR) infections CAMBRIDGE, Mass. , Oct. 29, 2025 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc.…
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (opens in a new tab)
CAMBRIDGE, Mass. , Oct. 14, 2025 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase 1b trial will be featured in an oral presentation at IDWeek 2025, taking place…
Genetic Analysis attends the Biomarkers & Precision Medicine congress in London (opens in a new tab)
OSLO, NORWAY, September 26, 2025: Microbiome DX company Genetic Analysis AS (“GA”) announces its attendance at the Biomarkers & Precision Medicine congress in London, 30 September – 01 October 2025. The event offers a chance to gain the latest insights from across the biomarker and precision medicine landscape, while p…
Genetic Analysis AS launches the GA-map® MHI GutHealth reagent kit (opens in a new tab)
OSLO, NORWAY – 24 September 2025: Microbiome DX company Genetic Analysis AS (“GA”) announces the launch of a novel Research Use Only (RUO) reagent kit, the GA-map® MHI GutHealth. The test provides an advanced tool for measuring antibiotic-induced microbiome imbalances and has been validated for recurrent Clostridioides…
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway (opens in a new tab)
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Company continues to engage in…
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference (opens in a new tab)
CAMBRIDGE, Mass. , Aug. 27, 2025 (GLOBE NEWSWIRE) — Seres Therapeutics , Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global Investment Conference in New York City and will present a company overview at 3:00…
Publication of Half-year report 2025 (opens in a new tab)
OSLO, NORWAY – August 27 2025: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the half-year report for H1, and April – June 2025. The Half-year report is available as an attached file to this release and on the Company’s website. Below is a summary of the report. Ronny Hermansen, CEO of Genetic Analysis, …
BioWorld – UK MHRA highlights potential of the vaginal microbiome in women’s health (opens in a new tab)
View article…
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates (opens in a new tab)
Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding…
Nature – Editor’s Pick: Freya Biosciences (opens in a new tab)
View article…
Genetic Analysis AS and Pangea Laboratory LLC announces the launch of GA-map® MHI GutHealth in the USA (opens in a new tab)
OSLO, NORWAY/IRVINE, CA, USA – 29 July 2025: Microbiome DX company Genetic Analysis AS (“GA”) and Pangea Laboratory LLC (“Pangea”) announces the launch of the GA-map® MHI GutHealth as a Research Use Only (RUO) test in the USA. As part of the collaboration Pangea will perform analysis in their CLIA-certified, CAP-accred…
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 (opens in a new tab)
CAMBRIDGE, Mass. , July 22, 2025 (GLOBE NEWSWIRE) — Seres Therapeutics , Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial…
Seres Therapeutics Announces Leadership Transition (opens in a new tab)
Thomas DesRosier and Marella Thorell , accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, including potential business development and…
Today is the last day for trading in the subscription rights for subscribing for shares in Genetic Analysis (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…